课题基金 / 基金详情

Sex as a Biological Variable Supplement - Molecular and cellular therapies against COVID-19 using angiotensin-converting enzyme 2 (ACE2)

Sex as a Biological Variable Supplement - Molecular and cellular therapies against COVID-19 using angiotensin-converting enzyme 2 (ACE2)
性别作为生物变量补充剂 - 使用血管紧张素转换酶 2 (ACE2) 针对 COVID-19 的分子和细胞疗法
批准号：
424669
负责人：
Zhang Haibo
金额：
$3.64万
依托单位：
Keenan Research Centre (Toronto, ON)
依托单位国家：
加拿大
项目类别：
Operating Grants
财政年份：
2020
资助国家：
加拿大
项目状态：
已结题
起止时间：
2020-04-01 至 2021-04-01
来源：
https://webapps.cihr-irsc.gc.ca/decisions/p/project_details.html?applId=424669&lang=en
关键词：
Biomedical Research Development Of New Therapeutics

项目摘要

项目成果

Zhang Haibo的其他基金

相似基金

相关文献

中文摘要
翻译
点击翻译按钮获取中文摘要
英文摘要
An epidemic caused by a novel coronavirus (SARS-CoV-2) has spread rapidly in China and 27 other countries. As of 15 February 2020, over 69,000 cases of COVID-19 have been reported, with 1,666 deaths. The enormous health, economic and social impact clearly
期刊论文(0)
专著(0)
科研奖励(0)
会议论文
Aiming at a new target in endotoxin-associated lung damage: The Ig domain 3 of ICAM-1
  • 批准号：
    479050
  • 项目类别：
    Operating Grants
  • 资助金额：
    $71.56万
  • 财政年份：
    2023
  • 负责人：
    Zhang Haibo
  • 依托单位：
    Unity Health Toronto
Aiming at a novel target in endotoxin-associated lung damage: The Ig domain 3 of ICAM-1
  • 批准号：
    477251
  • 项目类别：
    Operating Grants
  • 资助金额：
    $7.29万
  • 财政年份：
    2022
  • 负责人：
    Zhang Haibo
  • 依托单位：
    Unity Health Toronto
COVID-19 Variant Supplement - Molecular and cellular therapies against COVID-19 using angiotensin-converting enzyme 2 (ACE2)
Molecular and cellular therapies against COVID-19 using angiotensin-converting enzyme 2 (ACE2)
海外基金